BT062

DRUG2 trials

Sponsors

Biotest Pharmaceuticals Corporation

Conditions

Multiple Myeloma

Phase 1

Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT00723359

Biotest Pharmaceuticals CorporationMultiple Myeloma

Start: 2008-08-31End: 2012-04-30Updated: 2013-07-18

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT01001442

Biotest Pharmaceuticals CorporationMultiple Myeloma

Start: 2010-08-31End: 2016-03-31Updated: 2019-07-30